글로벌 기능성 장 질환 치료제 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 기능성 장 질환 치료제 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 유엔의 세계 인구 고령화 하이라이트 2020 연구에 따르면 전 세계 노인 인구는 2020년 7억 2,700만 명에서 2050년 15억 명으로 거의 두 배 증가할 것으로 예상되며, 2020년 노인 인구 비율은 약 9.3%였고 2050년까지 16%로 증가할 것으로 예상됩니다. 노인 인구는 기능성 장 질환의 위험이 높습니다. 이로 인해 의료 분야에서 기능성 장 질환 치료제에 대한 수요가 높아졌습니다.

Data Bridge Market Research는 기능성 장 질환 치료제 시장이 2021년에 20억 7,100만 달러 규모였으며 2029년까지 32억 5,000만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 5.80%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

과민성 대장 증후군, 만성 팽창, 설사 및 변비는 모두 기능성 장 장애 약물로 치료되며, 이는 증상을 완화하기 위해 다양한 방식으로 작용합니다. 전통적인 검사에서 병리학적 소견이 없는 만성 위장 (GI) 증상(예: 복통, 삼키기 어려움, 소화불량, 설사 , 변비 및 팽창)은 기능성 위장 장애(FGID)를 특징으로 합니다.

보고 범위 및 시장 세분화

기능성 장 질환 치료제 ? 시장 동향

운전자

• 기능성 위장관 질환(FGID)의 증가 발생

기능성 위장 장애(FGID)의 증가는 기능성 장 장애 치료제 시장의 성장에 영향을 미칠 것으로 예상됩니다. 흡연 중독 증가와 사람들의 앉아서 지내는 생활 방식은 FGID의 원인 중 일부입니다.

• 의료 인프라에 대한 투자 증가

기능성 장 질환 치료제 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 의료 서비스 지출이 증가하고 있다는 점인데, 이는 인프라를 개선하는 데 도움이 됩니다.

또한, 공공 및 민간 기관에서 인식을 확산하기 위한 이니셔티브가 증가함에 따라 기능성 장 질환 치료제 시장이 확대될 것입니다. 또한, 가처분 소득이 높고 스트레스와 우울증 사례가 증가함에 따라 기능성 장 질환 치료제 시장이 확대될 것입니다. 이와 함께 노령 인구가 증가하고 환급 정책이 유리해지면서 시장 성장률이 높아질 것입니다.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the functional bowel disorder agents? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the functional bowel disorder agents? market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the functional bowel disorder agents? market. Additionally, side effects of functional bowel disorder agents? and lack of awareness will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This functional bowel disorder agents? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the functional bowel disorder agents? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

functional gastrointestinal disorders (FGIDs) are quite frequent, with a global incidence of 40%. They are more common in women than in males, and their prevalence diminishes with age. They are responsible for 12% of primary care burden and 30% of gastrointestinal outpatient consultations. More over two-thirds of FGID patients will have seen a doctor in the previous year, and 40% will take regular medication. This increases the use of functional bowel disorder agents.

Functional bowel disorder agents? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Functional Bowel Disorder Agents? Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The functional bowel disorder agents market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the functional bowel disorder agents market's revenue trajectory.

Global Functional Bowel Disorder Agents? Market Scope

The functional bowel disorder agents? market is segmented on the basis of drug class, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Anticholinergics
• Chloride Channel Activators
• Guanylate Cyclase-C Agonists
• NHE3 Inhibitors
• Peripheral Opioid Receptor Antagonists
• Peripheral Opioid Receptor Mixed Agonists/Antagonists
• Serotoninergic Neuroenteric Modulators

On the basis of drug class, the global hepatic drugs market is segmented into anticholinergics, chloride channel activators, guanylate cyclase-C agonists, NHE3 inhibitors, peripheral opioid receptor antagonists, peripheral opioid receptor mixed agonists/antagonists, and serotoninergic neuroenteric modulators.

Application

• Irritable Bowel Syndrome
• Chronic Bloating
• Diarrhea
• Constipation
• Others

On the basis of application, the global hepatic drugs market is segmented into irritable bowel syndrome, chronic bloating, diarrhea, constipation and others.

Dosage

• Injection
• Tablet
• Others

On the basis of dosage, the functional bowel disorder agents? market is segmented into injection, tablet and others.  

Route of Administration

• Intravenous
• Oral
• Others

The route of administration segment for the functional bowel disorder agents? market is segmented into intravenous, oral and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the functional bowel disorder agents? market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the functional bowel disorder agents? market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Functional Bowel Disorder Agents Market Regional Analysis/Insights

The Functional bowel disorder agents? market is analysed and market size insights and trends are provided by country, drug class, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Functional bowel disorder agents? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the functional bowel disorder agents? market because of the well-established healthcare sector in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Functional Bowel Disorder Agents? Market Share Analysis

The Functional bowel disorder agents? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to functional bowel disorder agents? market.

Some of the major players operating in the functional bowel disorder agents? market are:

• Abbott (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.( Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Takeda Pharmaceutical Company Limited (Japan)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (영국)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 베링거 인겔하임 인터내셔널 GmbH. (독일)
• 아스텔라스파마 주식회사(일본)
• 알러간(아일랜드)
• 미쓰비시 타나베 파마 주식회사(일본)
• 교와기린 주식회사(일본)
• Liminal BioSciences Inc. (캐나다)
• Avexegen Therapeutics, Inc.(미국)
• AbbVie Inc.(미국)    

SKU-68166